TMS Ep73: Hotel sector, CP Gurnani, RBL Bank, Vaccine IP waiver
Europe is now adding a million new cases of Covid-19 every three days. In the United States, at least 190,000 new cases surface daily. China’s tally on Sunday was at its highest in 21 months. And, back in India, active cases topped 75,000 on Monday. The world is ringing the New Year with a feeling of déjà vu. The same goes for the hospitality industry, which was hoping to make up for its losses amid the New Year’s celebrations.
It is not just the hotel industry and tourism, the pandemic has cast its shadow on almost all sectors. The IT industry is also one of them. In a recent interview with Surajeet Das Gupta of Business Standard, CEO and Managing Director of Tech Mahindra, CP Gurnani, shared plans for growing his business amid the lingering uncertainty caused by Covid-19.
With half of its turnover coming from the telecom ecosystem, the IT major is now focusing on 5G, software-defined networks and connected solutions.
From Tech Mahindra’s growth plans, let’s move on to what’s happening in the stock market. The trading session was choppy on Monday, with benchmarks rallying sharply from the day’s lows, then strengthening in the latter part of the trading session. The holiday season in key markets and Omicron-related developments in the country topped the gains. So, what awaits you on Tuesday?
In addition to raising or disbursing funds in markets, companies around the world also spend heavily on research and development (R&D) and also reap the benefits of innovation. Intellectual property rights give them the power to produce it while prohibiting others from reproducing it. But, with humanity still in the dark about the future of the pandemic, should a few vaccine manufacturers and countries cling to their intellectual property rights and deny generic manufacturers the technologies to produce the vaccine? in large scale. A debate has been raging around him for some time now. Let us explore more about it in this podcast.
Watch the video